KR890001536A - Pharmaceutical compositions for improving blood lipid composition. - Google Patents

Pharmaceutical compositions for improving blood lipid composition. Download PDF

Info

Publication number
KR890001536A
KR890001536A KR1019870006805A KR870006805A KR890001536A KR 890001536 A KR890001536 A KR 890001536A KR 1019870006805 A KR1019870006805 A KR 1019870006805A KR 870006805 A KR870006805 A KR 870006805A KR 890001536 A KR890001536 A KR 890001536A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acid addition
addition salt
acceptable acid
acetoxy
Prior art date
Application number
KR1019870006805A
Other languages
Korean (ko)
Other versions
KR920003579B1 (en
Inventor
고오끼 다까시마
데쓰지 모리
다꾸 나가오
Original Assignee
마쓰바라이찌로
다나베 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마쓰바라이찌로, 다나베 세이야꾸 가부시끼가이샤 filed Critical 마쓰바라이찌로
Priority to KR1019870006805A priority Critical patent/KR920003579B1/en
Publication of KR890001536A publication Critical patent/KR890001536A/en
Application granted granted Critical
Publication of KR920003579B1 publication Critical patent/KR920003579B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음No content

Description

혈증 지질 조성을 개선시키기 위한 제약 조성물.Pharmaceutical compositions for improving blood lipid composition.

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (11)

2-(4-메톡시페닐)-3-아세톡시-5-[2-(디메틸아미노)에틸]-8-클로로-2,3-디히드로-1,5-벤저티아제핀-4-(5H)-온 또는 그의 제약상 허용되는 산부가염을 유효 성분으로 하고, 제약상 허용되는 담체와의 혼합물로 되는 혈중 지질 조성을 개선시키기 위한 제약 조성물.2- (4-methoxyphenyl) -3-acetoxy-5- [2- (dimethylamino) ethyl] -8-chloro-2,3-dihydro-1,5-benzithiazepine-4- (5H A pharmaceutical composition for improving blood lipid composition, which has a) -one or a pharmaceutically acceptable acid addition salt thereof as an active ingredient and is in admixture with a pharmaceutically acceptable carrier. 제1항에 있어서, 상기 유효 성분이 (+)-시스-2-(4-메톡시페닐)-3-아세톡시-5-[2-(디메틸아미노)에틸]-8-클로로-2,3-디히드로-1,,5-벤조티아제핀-4(5H)-온 또는 그의 제약성 허용되는 산부가염인 조성물.The compound according to claim 1, wherein the active ingredient is (+)-cis-2- (4-methoxyphenyl) -3-acetoxy-5- [2- (dimethylamino) ethyl] -8-chloro-2,3 -Dihydro-1,, 5-benzothiazepin-4 (5H) -one or a pharmaceutically acceptable acid addition salt thereof. 제1항에 있어서, 상기 제약상 허용되는 산부가염이 그의 염산염, 브롬화수소산염, 요오드화수소산염, 과염소산염, 황산염, 인산염, 옥살산염, 말레산염, 푸미르산염, 타르타르산염 및 메탄술폰산염 중에서 선택된 것인 조성물.The method according to claim 1, wherein the pharmaceutically acceptable acid addition salt is selected from hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate, phosphate, oxalate, maleate, fumarate, tartarate and methanesulfonate Composition. 제3항에 있어서, 상기 제약상 허용되는 산부가염이 말레산염인 조성물.4. The composition of claim 3 wherein said pharmaceutically acceptable acid addition salt is maleate. 제1항에 있어서, HDL-콜레스테롤양 대 총 혈청 콜레스테롤양의 비를 증가시키기 위한 제약 조성물.A pharmaceutical composition according to claim 1 for increasing the ratio of HDL-cholesterol amount to total serum cholesterol amount. 사람에게 제약상 유효량의 2-(4-메톡시페닐)-3-아세톡시-5-[2-(디메틸아미노)에틸]-8-클로로-2,3-디히드로-1,5-벤저티아제핀-4-(5H)-온 또는 그의 제약상 허용되는 산부가염을 투영하는 것을 특징으로 하는 혈증 지질 조성물을 개선시키는 방법.Pharmaceutically effective amount of 2- (4-methoxyphenyl) -3-acetoxy-5- [2- (dimethylamino) ethyl] -8-chloro-2,3-dihydro-1,5-benzithia to human A method of improving a hyperlipidemic composition characterized by projecting zepin-4- (5H) -one or a pharmaceutically acceptable acid addition salt thereof. 제6항에 있어서, 투여되는 화합물이 (+)-시스-2-(4-메톡시페닐)-3-아세톡시-5-[2-(디메틸아미노)에틸]-8-클로로-2,3-디히드로-1,,5-벤조티아제핀-4(5H)-온 또는 그의 제약성 허용되는 산부가염인 방법.The compound of claim 6, wherein the compound administered is (+)-cis-2- (4-methoxyphenyl) -3-acetoxy-5- [2- (dimethylamino) ethyl] -8-chloro-2,3 -Dihydro-1,, 5-benzothiazepin-4 (5H) -one or a pharmaceutically acceptable acid addition salt thereof. 제6항에 있어서, 상기 제약상 허용되는 산부가염이 그의 염산염, 브롬화수소산염, 요오드화수소산염, 과염소산염, 황산염, 인산염, 옥살산염, 말레산염, 푸마르산염, 타르타르산염 및 메탄술폰산염 중에서 선택되는 것인 방법.7. The pharmaceutically acceptable acid addition salt thereof according to claim 6, wherein the pharmaceutically acceptable acid addition salt is selected from hydrochloride, hydrobromide, hydroiodine, perchlorate, sulfate, phosphate, oxalate, maleate, fumarate, tartarate and methanesulfonate. How. 제8항에 있어서, 상기 제약상 허용되는 산부가염이 말레산염인 방법.The method of claim 8, wherein said pharmaceutically acceptable acid addition salt is maleate. 제6항에 있어서, 상기 화합물의 제약상 유효량이 3 내지 500mg/일인 방법.The method of claim 6, wherein the pharmaceutically effective amount of the compound is 3 to 500 mg / day. 제6항에 있어서, HDL-콜레스테롤양 대 총 혈청 콜레스테롤양의 비를 증가시키기 위한 방법.The method of claim 6, wherein the ratio of HDL-cholesterol amount to total serum cholesterol amount is increased. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임※ Note: The disclosure is based on the initial application.
KR1019870006805A 1987-07-01 1987-07-01 Pharmaceutical composition for improving constitution of lipids in blood KR920003579B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019870006805A KR920003579B1 (en) 1987-07-01 1987-07-01 Pharmaceutical composition for improving constitution of lipids in blood

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019870006805A KR920003579B1 (en) 1987-07-01 1987-07-01 Pharmaceutical composition for improving constitution of lipids in blood

Publications (2)

Publication Number Publication Date
KR890001536A true KR890001536A (en) 1989-03-27
KR920003579B1 KR920003579B1 (en) 1992-05-04

Family

ID=19262535

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870006805A KR920003579B1 (en) 1987-07-01 1987-07-01 Pharmaceutical composition for improving constitution of lipids in blood

Country Status (1)

Country Link
KR (1) KR920003579B1 (en)

Also Published As

Publication number Publication date
KR920003579B1 (en) 1992-05-04

Similar Documents

Publication Publication Date Title
KR950017957A (en) Preparation and intermediates of 3, 4, 4-trisubstituted-piperidinyl-N-alkylcarboxylates
UA41446C2 (en) Use of fumagilol or its derivatives for preparing drugs intended for treating intestinal infection and pharmaceutical composition
BR0210267A (en) Solid pharmaceutical composition, process for preparing same, obesity treatment set, composition use, obesity treatment process and lipase inhibitor
KR920702216A (en) Use of Acetyl D-Carnitine in Glaucoma Treatment
KR950016732A (en) How to suppress skin and vaginal atrophy
KR930700112A (en) Multifunctional pharmaceutical compound and method of using the same
KR960700061A (en) PHARMACEUTICAL COMPOSITION FOR TREATING NICOTINE DEPENDENCE
KR900005978A (en) Antimalarial Compositions and Methods of Treatment Using Kininidine, Artemisinin and Derivatives thereof
KR870008886A (en) 2-alkoxy-N- (1-azabicyclo [2,2,2] oct-3-yl) benzamide and thiobenzamide
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch
KR970061246A (en) Pharmaceutical Compositions for Increasing Testosterone
KR950016760A (en) Hemorrhoids Treatment
KR880009657A (en) Drugs with renal function and diuretic effect
US4806530A (en) Pharmaceutical compositions based on diltiazem and lysine acetylsalicylate
KR890001536A (en) Pharmaceutical compositions for improving blood lipid composition.
KR890004705A (en) Antiviral agents
KR940013503A (en) Pharmaceutical compositions for the prevention or treatment of atherosclerosis
KR870006035A (en) Preparation of New Antibacterial 1-thienyl-4-oxoquinoline-3-carboxylic Acid Compound
DE3585963D1 (en) SULFONATED RESINS WITH THERAPEUTIC EFFECTIVENESS, THE PRESENTATION AND THE MEDICINAL PRODUCTS CONTAINING THEM.
GB2190290B (en) Use of benzothiazepine derivatives in pharmaceutical compositions for improving constitution of lipids in blood.
KR890701111A (en) Treatment of dyslipidemia in humans
KR910015574A (en) Derivatives of 3-pyroglutamyl-thiazolidine-4-carboxylic acid and their pharmacological action
KR920703067A (en) L-α-glycerophoryl-D-myo-inositol for the treatment of peripheral neurological and brain diseases
FR2547730B1 (en) HYPOLIPIDEMIC DRUG CONTAINING AS ACTIVE INGREDIENT D-3-ACETOXY-CIS-2,3-DIHYDRO-5- (2- (DIMETHYLAMINO) ETHYL) -2- (P-METHOXYPHENYL) -1,5-BENZOTHIAZEPINE-4 (5H) -ONE OR ONE OF ITS SALTS OF ADDITION OF ACIDS ACCEPTABLE IN PHARMACY
KR890001562A (en) Atherosclerosis prevention and treatment

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
EXPY Expiration of term